Company intelligence / Profile preview

Aquarius Biotechnologies

Chicago, Illinois, United States

Ownership: Private
Employees: ~5
Development stage: Other

Overview

Lead program MAT2203 (oral amphotericin B): Phase 1 trial showed improved safety/tolerability; moving to Phase 2a in collaboration with NIH. MAT2501 (oral amikacin): Proof-of-principle animal data for Gram-negative bacteria; IND-enabling studies underway at acquisition date.

Therapeutic areas: Infectious Diseases
Modalities: Lipid nanoparticle delivery therapySmall moleculeBiologicAntibioticAntifungal
Industry: Biotech

Partnerships

National Institutes of Health (NIH; especially NIAID)Rutgers University (technology licensor)

Beyond the preview

Go deeper on Aquarius Biotechnologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aquarius Biotechnologies.

Explore the full profile